Metastatic carcinoma in effusions: Query primary site

Pathology Case Reviews

Volumn 11, Issue 2, 2006, Pages 74-77

  Filie, Armando C ^a,c   Jones, Heather D ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NONE   (United States)

Author keywords

Carcinoma; Effusion; Immunocytochemistry

Indexed keywords

AGED; CASE REPORT; CELL ULTRASTRUCTURE; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DYSPNEA; ELECTRON MICROSCOPY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; METASTASIS; PLEURA EFFUSION; PLEURA METASTASIS; PRIORITY JOURNAL; REVIEW; SMOKING; SYMPTOM; THORACOCENTESIS; WEIGHT REDUCTION;

EID: 33746638022     PISSN: 10829784     EISSN: 15334015     Source Type: Journal    
DOI: 10.1097/01.pcr.0000204656.36643.c2     Document Type: Review

References (26)

1. Monte SA, Ehya H, Lang WR. Positive effusion cytology as the initial presentation of malignancy. Acta Cytol. 1987;31:448-452.
2. Gupta RK, Kenwright DN, Fauck R, et al. The usefulness of a panel of immunostains in the diagnosis and differentiation of metastatic malignancies in pericardial effusions. Cytopathology. 2000;11:312-321.
3. Geisinger KR, Stanley MW, Raab SS, et al. Modern Cytopathology. Philadelphia, PA: Churchill Livingstone; 2004:257-309.
4. Murphy WM, Ng AB. Determination of primary site by examination of cancer cells in body fluids. Am J Clin Pathol. 1972;58:479-488.
5. Spieler P, Gloor F. Identification of types and primary sites of malignant tumors by examination of exfoliated tumor cells in serous fluids: comparison with the diagnostic accuracy on small histologic biopsies. Acta Cytol. 1985;29:753-767.
6. Bedrossian CWM. Diagnostic problems in serous effusions. Diagn Cytopathol. 1997;19:131-137.
7. Fetsch PA, Simsir A, Brosky K, et al. Comparison of three commonly used cytologic preparations in effusion immunocytochemistry. Diagn Cytopathol. 2002;26:61-66.
8. Mottolese M, Venturo I, Donnorso RP, et al. Use of selected combinations of monoclonal antibodies to tumor associated antigens in the diagnosis of neoplastic effusions of unknown origin. Eur J Cancer Clin Oncol. 1988;24:1277-1284.
9. Longatto Filho A, Alves VA, Kanamura CT, et al. Identification of the primary site of metastatic adenocarcinoma in serous effusions: value of an immunocytochemical panel added to the clinical arsenal. Acta Cytol. 2002;46:651-658.
10. Ng WK, Chow JC, Ng PK. Thyroid transcription factor-1 is highly sensitive and specific in differentiating metastatic pulmonary from extrapulmonary adenocarcinoma in effusion fluid cytology specimens: a study of 36 cases. Cancer (Cancer Cytopathol). 2002;96:43-48.
11. Gomez-Fernandez C, Jorda M, Delgado PI, et al. Thyroid transcription factor 1: a marker for lung adenoarinoma in body cavity fluids. Cancer (Cancer Cytopathol). 2002;96:289-293.
12. Afify AM, al-Khafaji BM. Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids. Acta Cytol. 2002;46:675-678.
13. Hecht JL, Pinkus JL, Weinstein LJ, et al. The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin. Am J Clin Pathol. 2001;116:483-488.
14. DeYoung BR, Wick MR. Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach. Semin Diagn Pathol. 2000;17:184-193.
15. Renshaw AA, Nappi D, Cibas ES. Cytology of metastatic adenocarcinoma of the prostate in pleural effusions. Diagn Cytopathol. 1996;15:103-107.
16. Saad RS, Essig DL, Silverman JF, et al. Diagnostic utility of CDX-2 expression in separating metastatic gastrointestinal adenocarcinoma from other metastatic adenocarcinoma in fine-needle aspiration cytology using cell blocks. Cancer (Cancer Cytopathol). 2004;102:168-173.
17. Lee BH, Hecht JL, Pinkus JL, et al. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol. 2002;117:745-750.
18. Fiel MI, Cernaianu G, Burstein DE, et al. Value of GCDFP-15 (BRST-2) as a specific immunocytochemical marker for breast carcinoma in cytologic specimens. Acta Cytol. 1996;40:637-641.
19. Ciampa A, Fanger G, Khan A, et al. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas. Cancer (Cancer Cytopathol). 2004;102:368-372.
20. Sack MJ, Roberts SA. Cytokeratins 20 and 7 in the differential diagnosis of metastatic carcinoma in cytologic specimens. Diagn Cytopathol. 1997;16:132-136.
21. Ascoli V, Taccogna S, Scalzo CC, et al. Utility of cytokeratin 20 in identifying the origin of metastatic carcinomas in effusions. Diagn Cytopathol. 1995;12:303-308.
22. Longatto Filho A, Bisi H, Alves VA, et al. Adenocarcinoma in females detected in serous effusions: cytomorphologic aspects and immunocytochemical reactivity to cytokeratins 7 and 20. Acta Cytol. 1997;41:961-971.
23. Jang KY, Kang MJ, Lee DG, et al. Utility of thyroid transcription factor-1 and cytokeratin 7 and 20 immunostaining in the identification of origin in malignant effusions. Anal Quant Cytol Histol. 2001;23:400-404.
24. Stopyra GA, Warhol MJ, Multhaupt HA. Utility of CK7 and CK20 immunohistochemistry in the detection of synchronous breast and colon carcinoma in a pleural effusion: a case report and supporting survey of archival material. Diagn Cytopathol. 2001;25:54-58.
25. Hanna W, Kahn HJ. The ultrastructure of metastatic adenocarcinoma in serous fluids: an aid in identification of the primary site of the neoplasm. Acta Cytol. 1985;29:202-210.
26. Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11:3766-3772.